Retour aux projets

14603.1;5 PFLS-LS

Proof-of-Concept: Human FAP-targeting Antibodies as Infarction Prevention Medications

Résumé

Proof-of-Concept: Human FAP-targeting Antibodies as Infarction Prevention Medications

Textes supplémentaires

Abstract

FlowMab is a human monoclonal antibody based medication designed to be administered to high-risk patients to reduce their acute and sub-acute risk of infarction. In this project, FlowMab drug candidates will be generated by Mabimmune for proof-of-concept testing in human biopsies and animal models at the Cardiovascular Research Group, Department of Surgical Research, University Hospital Zurich. This study is anticipated to result in proof-of-concept data of lead candidates necessary for: 1. Securing a partnership with a large industry partner for human clinical trials, 2. Improving FlowMab¿s risk profile for human trials, and 3. cueing the development of a companion diagnostic FAP blood test.

Participants

Simon Philipp Hoerstrup

Kontaktperson

simon_philipp.hoerstrup@chi.usz.ch

Universitätsspital Zürich Simon Philipp Hoerstrup Moussonstrasse 13 8091 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2012-09-30
Date de fin
2015-07-21
Coûts totaux approuvés
CHF 295140.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T115 Medical technology 100.0%